Respiratory syncytial virus (RSV) vaccine candidate


MVA-BN RSV is our product candidate in clinical development for the  prevention of RSV. The vaccine has been specifically designed to target 5 different RSV proteins to ensure a broad immune response against both RSV subtypes (A & B). Extensive preclinical studies have shown that MVA-BN RSV induces a balanced immune response comprised of both antibodies and T cells, in a similar fashion to the natural response to an RSV infection.

Results from a Phase 1 study in 63 healthy adults, aged 18-65, were reported in May 2016, demonstrating that MVA-BN RSV was well tolerated  and induced a significant increase in antibodies and T cells in humans against both RSV subtypes. Also of note was the production of IgA, a specialized antibody that is transported from the blood to the mucosal surfaces (e.g. nose, throat, lungs) potentially allowing for protection against RSV at the point of infection/inflammation. These results provide a clear rationale for moving into larger trials, and Bavarian Nordic initiated a Phase 2 dose finding study in 400 elderly subjects in October 2016. Top line results from this study were announced in June 2017.

RELATED INformation

June 27, 2017
Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine

February 23, 2017
Updated Phase 1 Data Show Bavarian Nordic’s Vaccine Candidate Induces a Broad and Durable Immune Response against RSV

December 14, 2016
Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine

October 18, 2016
Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine

May 23, 2016
Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations